Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Blood blood.2024024968.

https://doi.org/10.1182/blood.2024024968

Published: 2024

Includes: Supplemental data

Journal Articles

A menin-KMT2A inhibitor to overcome resistance

Caroline A. Heckman

Blood (2024) 144 (11): 1139–1140.

https://doi.org/10.1182/blood.2024025760

Published: 2024

Journal Articles

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Ida Vänttinen, Tanja Ruokoranta, Joseph J Saad, Sari Kytölä, Monica Hellesøy, Stein-Erik Gullaksen, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Krister Wennerberg, Bjorn T. Gjertsen, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki

Blood (2023) 142 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2023-189340

Published: 2023

Journal Articles

Label-Free High Dimensional Single Cell Morphological Profiling of Different Hematological Malignancies By Ghost Cytometry

Asako Tsubouchi, Juho Jalmari Miettinen, Keisuke Wagatsuma, Satoru Akai, Yuri An, Mika Uematsu, Philipp Sergeev, Dimitrios Tsallos, Markus Vaha-Koskela, Sadao Ota, Caroline A. Heckman

Blood (2023) 142 (Supplement 1): 5347.

https://doi.org/10.1182/blood-2023-188393

Published: 2023

Journal Articles

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Blood (2023) 142 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2023-174891

Published: 2023

Journal Articles

Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia

Ankita Srivastava, Caroline A. Heckman, Juho Jalmari Miettinen, Olivier Harismendy

Blood (2023) 142 (Supplement 1): 5007.

https://doi.org/10.1182/blood-2023-188608

Published: 2023

Journal Articles

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

Bridget A Robinson, Philipp Sergeev, Yoko Kosaka, Thomas Jacob, Andy Kaempf, Evan F. Lind, Cristina Tognon, Luis A. Carvajal, Jorge F. DiMartino, Caroline A. Heckman, Tania Q Vu

Blood (2023) 142 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2023-186506

Published: 2023

Journal Articles

The Impact of the Peptide Drug Conjugate Melflufen on the Myeloma Tumour Microenvironment

Philipp Sergeev, Juho Jalmari Miettinen, Stefan Svensson Gelius, Klara Acs, Caroline A. Heckman

Blood (2023) 142 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2023-188603

Published: 2023

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Joseph Saad, Samuli Eldfors, Vilma Ikonen, Bjørn Tore Gjertsen, Mika Kontro, Kimmo Porkka, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 1033–1035.

https://doi.org/10.1182/blood-2022-163242

Published: 2022

Journal Articles

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Blood (2022) 140 (Supplement 1): 1030–1032.

https://doi.org/10.1182/blood-2022-159069

Published: 2022

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

Journal Articles

Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project

Blood (2022) 140 (Supplement 1): 13122–13124.

https://doi.org/10.1182/blood-2022-163285

Published: 2022

Journal Articles

The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies

Juho J. Miettinen, Tanja Ruokoranta, Vilma Ikonen, Maiju-Emilia Huppunen, Klara Acs, Fredrik Lehmann, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 10697–10698.

https://doi.org/10.1182/blood-2022-166090

Published: 2022

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Blood (2022) 140 (Supplement 1): 2020–2022.

https://doi.org/10.1182/blood-2022-159391

Published: 2022

Journal Articles

A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma

Philipp Sergeev, Sadiksha Adhikari, Juho J. Miettinen, Maiju-Emilia Huppunen, Minna Suvela, Ana Slipicevic, Nina N. Nupponen, Klara Acs, Fredrik Lehmann, Caroline A. Heckman

Blood (2022) 140 (Supplement 1): 6000–6001.

https://doi.org/10.1182/blood-2022-162182

Published: 2022

Journal Articles

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Blood (2022) 140 (17): 1891–1906.

https://doi.org/10.1182/blood.2021015106

Published: 2022

Includes: Supplemental data

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2021-149521

Published: 2021

Journal Articles

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Tommaso Matteuzzi, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, Julia Krzykalla, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Alberto Hernandez-Sanchez, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Herve Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Raúl Azibeiro Melchor, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Marta Sobas, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel van Speybroeck, Renate Schulze-Rath, Jesús M Hernández Rivas, Brian J.P Huntly, Hartmut Döhner, Gert J. Ossenkoppele, Castellani Gastone, Lars Bullinger

Blood (2021) 138 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2021-152215

Published: 2021

NARROW

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

A menin-KMT2A inhibitor to overcome resistance

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Label-Free High Dimensional Single Cell Morphological Profiling of Different Hematological Malignancies By Ghost Cytometry

The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

The Impact of the Peptide Drug Conjugate Melflufen on the Myeloma Tumour Microenvironment

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project

The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma

Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only